Novavax COVID-19 vaccine, codenamed NVX-CoV2373, and als...
wikipedia - 20 Jan 2022Novavax COVID-19 vaccine, codenamed NVX-CoV2373, and also called SARS-CoV-2 rS (recombinant spike) protein nanoparticle with Matrix-M1 adjuvant, is a COVID-19 vaccine candidate developed by Novavax and Coalition for Epidemic Preparedness Innovations (CEPI). It requires two doses[1] and is stable at 2°C to 8°C (refrigerated).[2]